Golden Sunrise Nutraceutical
Golden Sunrise Nutraceutical
  • GOLDEN SUNRISE
  • PRODUCTS
  • SCIENCE
  • REAL WORLD EVIDENCE
  • NEWS
  • TEAM
  • PIPELINE
  • COST
  • CONTACT
  • More
    • GOLDEN SUNRISE
    • PRODUCTS
    • SCIENCE
    • REAL WORLD EVIDENCE
    • NEWS
    • TEAM
    • PIPELINE
    • COST
    • CONTACT
  • GOLDEN SUNRISE
  • PRODUCTS
  • SCIENCE
  • REAL WORLD EVIDENCE
  • NEWS
  • TEAM
  • PIPELINE
  • COST
  • CONTACT

Corporate Updates

* On November 04, 2026, the FDA Center for Drug Evaluation and Research (CDER) collected the comments from Golden Sunrise Nutraceutical (Golden Sunrise) and author CDER publicly posts electronic and paper docket of Golden Sunrise documents on Regulations.gov under section SEARCH "FDA-2026-N-9550-0038" then tab COMMENTS "Comment from Golden Sunrise Nutraceutical, Inc."  First published in Year-2004 and updated in Year-2016, the FDA Botanical Drug Development Guidance provides a specialized pathway for plant-derived or botanical medicines.  Unlike synthetic single-molecule drugs, this pathway accommodates complex chemical mixtures and allows documented prior human use to help support Phase I and Phase II safety evidence.  Botanical products are legally distinct from herbal dietary supplements regulated under the Year-1994 Dietary Supplement Health and Education Act (DSHEA).  Dietary supplement products DO NOT require pre-market FDA-approval process or Clinical Trials to prove efficacy, whereas botanical products must complete full New Drug Application (NDA) reviews.  * In August 27, 2026, the Advancing Botanical Drug Development Act of 2026 (H.R. 10150) was introduced in U.S. Congress to address market incentives by proposing regulatory exclusivity periods for qualifying botanical drug products.  ** In September 03, 2026, the FDA opened a Public Docket No.: FDA-2026-N-9550 requesting stakeholder information on current development hurdles and potential updates to botanical products evaluation.



* On November 02, 2026, The FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality.  FDA issues Final Guidance for cell and gene therapy manufactures, recommends building potency assurance into every stage of a therapy's lifecycle - from early development through patient delivery.  The Potency Assurance for Cellular and Gene Therapy Products final guidance replaces FDA's Year-2011 potency testing guidance for Cellular and Gene Therapy products and applies to treatments for Serious and often Life-threatening conditions.  By law, manufacturers are expected to verify that their products work as intended, from the time of approval through Post-approval Monitoring (PAM).  This final guidance provides FDA's current thinking and recommendations on how manufactures can meet that requirement.  "Patients who receive cellular and gene therapies are often battling Serious or Life-threatening conditions, such as Cancers and are rare diseases."  Read more.....



* On October 30, 2026, American Medical Association (AMA) Press Releases: AMA Urges FDA to Pursue Safety Standards for Botanical Products.  * AMA letter to FDA Deputy Commissioner Grace R. Graham, the AMA emphasized that botanical products—including kratom, cannabis and other plant-derived substances—should be subject to the same scrutiny as other drugs.  Growing consumer use, anecdotal claims and marketing by social media influencers should not circumvent the FDA approval process or replace the requirement for high-quality clinical trials and Postmarket safety monitoring.  Read more..... In a letter to the FDA dated October 28, 2026 (PDF).



* On September 03, 2026, The FDA Seeks Public Input to Advance Development of Botanical Drug Products.  The FDA issues Request for Information (RFI) to gather public input on opportunities to advance the development of botanical drug products.  Botanical drug products are products that include or may be derived from plant materials, algae, macroscopic fungi, or combinations of these materials and are intended to diagnose, cure, mitigate, treat or prevent disease.  "Under the Trump Administration, we are committed to modernizing regulatory frameworks to ensure promising, natural health options are evaluated through rigorous science."  Through the RFI, the FDA is seeking feedback on topics including challenges encountered in botanical research and drug development; innovative approaches to support and accelerate development; potential updates to FDA guidance and other resources; quality standards; appropriate study designs for complex botanical mixtures; and the potential use of Real World Evidence and other scientifically credible information to facilitate development.  Read more.....



* On August 27, 2026 - Congresswoman Lauren O. BOEBERT Introduces Advancing Botanical Drug Development Act of Year-2026 (H.R. 10150) to provide a 12-years market exclusivity period for FDA-Approved Botanical Drugs.  Read more.....



* On June 04, 2026, Google Developer Team and September 06, 2026, Apple Store Connect has been accepted for NutraCoin App to install in Google Play and Apple Store - Nutracoin is a digital platform designed to help investors manage their NutraCoin balance in one secure and simple place.  Users can view their token balance, track account activity, and manage buy/sell requests through the app.  The platform is built for easy access, transparency, and future blockchain integration.  Read more..... Google Play and Apple Store.



* On May 12, 2026, U.S. Federal Trade Commission (FTC) sends checks to consumers who brought certain products from Golden Sunrise Nutraceutical (Golden Sunrise) between Year-2017 and Year-2020.  Read more.....  The FTC payout that was gained notoriety was from Stephen R. MEIS (Dr. Meis) whom FTC cohered one hundred three thousand four hundred twenty ($103,420.00) dollars settlement on May 11, 2021, and was NOT involved regarding the Golden Sunrise case Court order on October 20, 2025.  The FTC payout was in sum of twenty ($20.00) dollars to individuals who did NOT pay for any Golden Sunrise products.  The FTC chose to send money to random individuals to justify their settlement, but this was NOT a judgement of the Court order on October 20, 2025.



* On December 02, 2025, an FDA inspection of Golden Sunrise Nutraceutical facilities was classified as No Action Indicated (NAI), and FDA Establishment Inspection Report No.: 3014549624.  Martin F. LOEFFLER (Loeffler) and Huu S. TIEU (Mr. Tieu) were present during inspection and closeout interview.  As quoted by the FDA Inspection Affidavit signed by Mr. Tieu on December 16, 2025, stating "I attest that the firm's customers consist of medical groups and doctors throughout the United States which purchase the firm's products via healthcare and using value-based healthcare incentives for physicians to treat patients with chronic conditions such as various cancer or other various stages of Serious or Life-threatening diseases."  Read more.....



* On October 20, 2025, Case No.: 1:20-cv-01060-DJC-SKO, Judge Daniel J. CALABRETTA ordered in favor of the Federal Trade Commission (FTC) against Golden Sunrise Nutraceutical/Golden Sunrise Pharmaceutical (Golden Sunrise), Mr. Tieu, and Stephen R. MEIS Motion for Summary Judgment and Permanent Injunction was GRANTED.  Golden Sunrise is still allowed to continue doing business without paying a civil penalty to the FTC and without returning money to consumers.  CASE CLOSED.



* September 26, 2025, Golden Sunrise Nutraceutical, Inc. announced that they created a digital platform for Real World Asset Tokenization that benefits investors to manage their NutraCoin to manage their NutraCoin token buy or sell requests through the app.  Read more.....



* On June 23, 2025, Anthem Blue Cross pays for Cellular Therapy treatment for Life-threatening situations to Oakview Medical Group.  The Federal Food, Drug, and Cosmetic Act (FD&C Act) Title 21 U.S.C. §352(a)(1) ".......drugs or devices for coverage or reimbursement, shall not be considered to be false or misleading under this paragraph if the Health Care Economic Information relates to an indication approved under section 355, 360(k), 360c(f)(2), or 360e......"  Read more.....



* On June 20, 2025, U.S. Securities and Exchange Commission (SEC) had accepted Golden Sunrise Nutraceutical, Inc. (Golden Sunrise) submission and CIK No.: 0001705521 as a Regulation Form D Rule 506(c).  The SEC had successfully received notice of an exemption for Golden Sunrise Private Placement Offering.  Read more.....



* On January 18, 2025, Cigna Health and Life Company pays for Cellular Therapy treatment for chronic conditions to Oakview Medical Group.  The Federal Food, Drug, and Cosmetic Act (FD&C Act) Title 21 U.S.C. §352(a)(1) ".......drugs or devices for coverage or reimbursement, shall not be considered to be false or misleading under this paragraph if the Health Care Economic Information relates to an indication approved under section 355, 360(k), 360c(f)(2), or 360e......"  Read more.....



* On November 05, 2024, FDA inspection Golden Sunrise Nutraceutical facilities.  Martin F. LOEFFLER (Mr. Loeffler) President and Huu S. TIEU (Mr. Tieu) were present during closeout interview "No objectionable conditions were discussed and Form FDA-483 was not issued."  As quoted by the FDA Inspection Affidavit signed by Mr. Loeffler on November 21, 2024, stating "The dietary supplements are given to treat patients in various of Serious or Life-threatening diseases, including different stages of Cancer."



* On June 12, 2024, Case No.: 1:20-cr-00109-BAM-1, Magistrate Judge Barbara A. McAuliffe ordered Court made findings and imposed the sentencing Huu S. TIEU as to Counts I, II, and III, all to be served consecutively, for a total term of 18-months.  Supervised Release: 12-months on Counts I, II, and III, all to be served concurrently, for a total term 12-months with standard and special conditions.  Fine: Ten thousand ($10,000.00) dollars.  Special Assessment: seventy-five ($75.00) dollars.  Appeal rights given.  Oral motion by the government to dismiss the indictment was GRANTED.  Government waived right to seek Forfeiture.  CASE CLOSED.



* March 25, 2023, the Porterville Recorder "MedEd Meetings inviting Huu S. TIEU as a speaker to the World Diabetes & Endocrinology Conference (WDEC) Year-2023 to be held during October 09 - 11, 2023, in BARCELONA Spain".  Read more.....



* On September 16, 2020, the FDA Consumer Safety Officer forwarded Golden Sunrise Nutraceutical (Golden Sunrise) products the Center for Biologics Evaluation and Research (CBER) which then moved forward to the FDA Product Jurisdiction Officer (PJO) Title 21 U.S.C. §3.8(b) and §3.7(c)(3) to determine the jurisdiction of Golden Sunrise products.  Read more.....



* On September 14, 2020, the FDA COVID-19 Product Development Team assigned Prioritized Review Expedited No.: 2020-2867 CR2020-2596 to Golden Sunrise Pharmaceutical/Golden Sunrise Nutraceutical (Golden Sunrise) and FDA requested COVID-19 patient medical results.  Golden Sunrise submitted fifty-four COVID-19 patient medical results for evaluation and classification of Golden Sunrise products.



* On August 26, 2020, the FDA COVID-19 Product Development Team requesting the COVID-19 patient medical results from Golden Sunrise Nutraceutical/Golden Sunrise Pharmaceutical (Golden Sunrise) to expedited review and classification.  The COVID-19 Product Development Team stated "Please refer to Tracking No.: 435 when you respond."



* On July 31, 2020, the U.S. Federal Trade Commission (FTC) sued Golden Sunrise Nutraceutical/Golden Sunrise Pharmaceutical (Golden Sunrise), Huu S. TIEU, and Stephen R. MEIS for selling fake, expensive treatment plans that falsely claimed to cure COVID-19, Cancer, and Parkinson's disease.  Read more.....



* On July 09, 2020, Case No.: 1:20-cr-0109-DAD-BAM the U.S. Attorney's Office Eastern District of California filed indictment charging Huu S. TIEU (Mr. Tieu) in violation of 18 U.S.C. § 1341; three (3) counts of Introduction of Misbranded Drug Into Interstate Commerce with the Intent to Defraud or Mislead in violation of 21 U.S.C. §§ 331(a) and 333(a)(2); and seeking Criminal Forfeiture under 18 U.S.C. §§ 981(a)(1)(C), 982(a)(7), 21 U.S.C. § 334, and 28 U.S.C. § 2451(c).  Read more.....



* On June 12, 2020, the U.S. Federal Bureau of Investigation law enforcement (FBI) actions targeting Golden Sunrise Nutraceutical/Golden Sunrise Pharmaceutical (Golden Sunrise) involved a massive crackdown on fraudulent medical claims.  Read more.....



* On May 15, 2020, The Porterville Recorder "Two more COVID-19 patients say treatments has helped them: They were treated with combination of supplement, cleansers".  Read more.....



* On April 09, 2020, The Porterville Recorder "COVID-19 patient says herbal treatment helping her: RN says Golden Sunrise Pharmaceutical has her feeling better".  Read more .....



* On April 09, 2020, Golden Sunrise Nutraceutical/Golden Sunrise Pharmaceutical (Golden Sunrise) submitted to "FDA Request for Designation" and "Letter of Notification" regarding Emergency D-Virus Plan of Care treatment of COVID-19.



* On April 05, 2020, the FDA COVID-19 Product Development Team assigned the Tracking No.: 435 and Triaged to Golden Sunrise Nutraceutical/Golden Sunrise Pharmaceutical (Golden Sunrise).



* On April 03, 2020, Golden Sunrise Nutraceutical/Golden Sunrise Pharmaceutical (Golden Sunrise) submitted supplemental New Drug Application (sNDA) No.: 204701 under section Proposed Indication for Use: COVID-19 and Serious or Life-threatening conditions to FDA COVID-19 Product Development Team.



* On March 30, 2020, the FDA formally established the Coronavirus Treatment Accelerate Program (CTAP), an emergency program designed to expedite the development of safe and effective treatments for patients fighting COVID-19.  During this public health emergency associated with the COVID-19 pandemic, the Office of Combination Products (OCP) was requesting applications/sponsors to submit Request for Designation (RFDs), and Pre-RFDs electronically.  The OCP issues classification and jurisdiction assignments for human medical products.  The classification of a product determines the type of a product or combination of products.  Jurisdiction determines the FDA Center or Lead Center (CBER, CDER, or CDRH) that will regulate the product.



* On February 19, 2019, the FDA conducted and inspection of Golden Sunrise Nutraceutical/Golden Sunrise Pharmaceutical (Golden Sunrise) facilities and upon completion classified as Voluntary Action Indicated (VAI).  FDA Establishment Inspection Report No.: 3012327979, Huu S. TIEU (Mr. Tieu) President was the only person present during the closeout interview "No objectionable conditions were discussed and Form FDA-483 was not issued."  Mr. Tieu signed an affidavit dated March 22, 2019.



* On February 19, 2019, FDA Expedited Programs for Regenerative Medicine Therapies for Serious Conditions Guidance for Industry.  This guidance provides sponsors engaged in the development of regenerative medicine therapies for Serious or Life-threatening diseases or conditions with our recommendations on the expedited development and review of these therapies, including as provided under section 506(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as added by section 3033 of the 21st Century Cures Act (Cures Act).  Under section 506(g) of the U.S. Federal Food Drug, and Cosmetic Act (FD&C Act), a regenerative medicine therapy can be designated as a regenerative advanced therapy if it meets certain criteria.  FDA refers to such designation as “Regenerative Medicine Advanced Therapy” (RMAT) designation.  This guidance describes the expedited programs available to sponsors of regenerative medicine therapies for serious conditions, including those products designated as RMATs.  To that end, the guidance provides information about the provisions in the Cures Act regarding the use of the Accelerated Approval pathway for regenerative medicine therapies that have been granted designation as an RMAT.  Finally, the guidance describes considerations in the clinical development of regenerative medicine therapies and opportunities for sponsors of such products to interact with CBER review staff.  Read more..... and [Federal Register Volume 84, Number 33  on Tuesday, February 19, 2019] [Notices] [Pages 4825-4826].  From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2019-02691].  Read more.....



* On January 30, 2019, FDA Regenerative Medicine Advanced Therapy (RMAT) letter to Golden Sunrise Pharmaceutical/Nutraceutical (Golden Sunrise) with FDA Reference No.: PS003231.  FDA RMAT stated "* Acknowledge receipt of your message and attached document.  ** I have forwarded your documents to the reviewers to draft a response for you.  *** I noted that the number reference [NDA 204701] is a file that is managed by the Center for Drug Evaluation and Research.  **** Our office review the applications for Regenerative Medicine Advanced Therapy requests and this office is under Center for Biologics Evaluation and Research.  ***** Thank you for submitting the request information."



* On November 05, 2018, Golden Sunrise Pharmaceutical submitted the New Drug Application (NDA) No.: 204701 under the section Proposed Indication for Use: Serious or Life-threatening conditions to FDA Regenerative Medicine Advanced Therapy (RMAT) Team, the submission triggers a rigorous evaluation process that includes a mandatory manufacturing and facility evaluation know as a Pre-Approval Inspection (PAI).



* On May 10, 2017, U.S. Securities and Exchange Commission (SEC) had accepted Golden Sunrise Pharma, Inc. (Golden Sunrise) submission and CIK No.: 0001705521 as a Regulation Form D Rule 506(b).  The SEC has successfully received notice of an exemption for Golden Sunrise Private Placement Offering.  Read more.....



* On April 08, 2017, Golden Sunrise Pharmaceutical/ Nutraceutical (Golden Sunrise) responded to FDA Regenerative Medicine Advanced Therapy (RMAT) letter dated April 06, 2017, regarding a DENY to evaluate Golden Sunrise product for RMAT designation.  Golden Sunrise stated "Golden Sunrise would ask you please refer to the Section 506(g)(1) and 506(g)(7) of the 21st Century Cures Act (Cures Act) as a drug is intended to treat, modify, reverse, or cure a Serious or Life-threatening disease or condition."  Read more.....



* On April 06, 2017, FDA Regenerative Medicine Advanced Therapy (RMAT) designation DENY Golden Sunrise Pharmaceutical/Nutraceutical (Golden Sunrise) letter  dated February 16, 2017, request for RMAT designation.  FDA stated "We have reviewed your request and have determined that your product, a botanical product, is not a regenerative medicine therapy, which is defined in Section 506(g)(3) and 506(g)(8) of the Act as including certain cellular and tissue-based products and therapies."  Read more.....



* On March; 2017, FDA introduced the new Regenerative Medicine Advanced Therapy (RMAT) designation thus recognizing the enormous potential of these medicines and the need for efficient regulatory tools to accelerate their development and their commercial availability.  The development of regenerative medicines is very challenging because of their complex and unique nature, especially to the rather unexperienced small- and medium-sized developing enterprises.  With the new RMAT designation, FDA aims at providing intensive support to companies developing cell- and tissue-based therapies, tissue-engineering products, and combination treatments.  This may also include cell-based products where the genome has been edited by emerging technologies such as CRISPR-Cas9.  This article presents the newly launched RMAT designation, outlines existing FDA regulatory tools aiming at expediting approval, and discusses the overall value of these programs.  Additionally, recommendations are provided for companies developing these very specific and complex therapies on how and when to consider these tools for an integrated development and regulatory strategy.  Read more.....



* On February 16, 2017, Golden Sunrise Pharmaceutical (Golden Sunrise) submitted a letter to the U.S. Food and Drug Administration (FDA) requesting evaluation and classification of Golden Sunrise dietary supplement product is a new Breakthrough Therapy that treats patients with Serious or Life-threatening diseases or conditions that already has a New Drug Application (NDA) number.



** On December 13, 2016, President Barack H. OBAMA signed the 21th Century Cures Act into law to speed up new medical product development and delivery of new medical treatments to patients faster.  The bill incorporated the Helping Families In Mental Health Crisis Act, first introduced by then-Congressman Tim F. MURPHY.  Read more.....


REFERENCE

Huu S. TIEU Request for FDA to Establish Regenerating Human Cells as Law on December 13, 2016 President Barack H. Obama Signed the 21st Century CURES Act 



* On March 04, 2016, the FDA assigned to Golden Sunrise Pharmaceutical the New Drug Application (NDA) No.: 204701 to identify each formal marketing application for a new drug.

* On April 19, 2013, the FDA assigned a Pre-Investigational New Drug (Pre-IND) No.: 117507 under the regulation of the U.S. Federal, Drug, and Cosmetic Act (FD&C Act) Title 21 §505(b)(1).  FDA stated "Once you have successfully addressed all the items listed above and below, you may be able to conduct a small well-designed study in a few patients."



* On February 22, 2010, the FDA assigned a Pre-Investigational New Drug (Pre-IND) Consultation meeting for a formal advisory consultation before submitting an Investigational New Drug (IND) application for evaluation process and classification.  Also, the FDA refers to "FDA Guidance for Industry - Botanical Drug Products" for recommendations relevant to the non-clinical development of Golden Sunrise Nutraceutical (Golden Sunrise) New Medical Innovation in Botanical Cellular Therapy.  Read more.....



* On November 15, 2007, Huu S. TIEU (Mr. Tieu) submitted a letter to the U.S. Food and Drug Administration (FDA) for a meeting regarding an evaluation of the New Medical Innovation products to treat patients in Life-threatening situations.  Emergency Exemption from Prospective Institutional Review Broad (IRB) Approval: Life-threatening situations for the purposes of Title 21 U.S.C. §56.102(d), includes the scope of both life-threatening and severely debilitating, as defined below.  Under Emergency Use an Investigational Drug or Biologic.  Read more.....

Copyright 2026 Golden Sunrise Nutraceutical - All Rights Reserved.

  • GOLDEN SUNRISE
  • TEAM
  • PIPELINE
  • COST

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept